AMEX:OCX (USA) Also Trade In: Germany UK

OncoCyte Corp $ 4.92 -0.42 (-7.87%)

Volume:
947,838
Avg Vol (1m):
1,539,993
Market Cap $:
431.04 Mil
Enterprise Value $:
428.83 Mil
PE Ratio:
0.00
PB Ratio:
9.55
Warning! GuruFocus has detected 3 Good signs with OCX. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for OCX (OncoCyte Corp) from 2015 to Feb 28 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. OncoCyte stock (OCX) PE ratio as of Feb 28 2021 is 0. More Details

OncoCyte PE Ratio (TTM) Chart

EMBED

OncoCyte PE Ratio (TTM) Historical Data

Total 1240
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
OncoCyte PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-02-280.0 2020-12-230.0
2021-02-260.0 2020-12-220.0
2021-02-250.0 2020-12-210.0
2021-02-240.0 2020-12-180.0
2021-02-230.0 2020-12-170.0
2021-02-220.0 2020-12-160.0
2021-02-190.0 2020-12-150.0
2021-02-180.0 2020-12-140.0
2021-02-170.0 2020-12-110.0
2021-02-160.0 2020-12-100.0
2021-02-150.0 2020-12-090.0
2021-02-120.0 2020-12-080.0
2021-02-110.0 2020-12-070.0
2021-02-100.0 2020-12-040.0
2021-02-090.0 2020-12-030.0
2021-02-080.0 2020-12-020.0
2021-02-050.0 2020-12-010.0
2021-02-040.0 2020-11-300.0
2021-02-030.0 2020-11-270.0
2021-02-020.0 2020-11-250.0
2021-02-010.0 2020-11-240.0
2021-01-290.0 2020-11-230.0
2021-01-280.0 2020-11-200.0
2021-01-270.0 2020-11-190.0
2021-01-260.0 2020-11-180.0
2021-01-250.0 2020-11-170.0
2021-01-220.0 2020-11-160.0
2021-01-210.0 2020-11-130.0
2021-01-200.0 2020-11-120.0
2021-01-190.0 2020-11-110.0
2021-01-150.0 2020-11-100.0
2021-01-140.0 2020-11-090.0
2021-01-130.0 2020-11-060.0
2021-01-120.0 2020-11-050.0
2021-01-110.0 2020-11-040.0
2021-01-080.0 2020-11-030.0
2021-01-070.0 2020-11-020.0
2021-01-060.0 2020-10-300.0
2021-01-050.0 2020-10-290.0
2021-01-040.0 2020-10-280.0
2020-12-310.0 2020-10-270.0
2020-12-300.0 2020-10-260.0
2020-12-290.0 2020-10-230.0
2020-12-280.0 2020-10-220.0
2020-12-240.0 2020-10-210.0

OncoCyte PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries 7OC.Germany 0KCC.UK OCX.USA
Address 15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.